Further, later improvements may be related to the centralisation of breast cancer management and the introduction of further treatment breakthroughs, such as taxanes (1994), trastuzumab (1998) and aromatase-inhibitors (2004)17. The gene discussed is CYP19A1; the disease is breast carcinoma.